Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELGN-2112 safety and feeding study in very preterm and growth-restricted infants
2022-004195-42Phase 2Active
- Sponsor
- Elgan Pharma
- Start
- Jan 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in intestinal malabsorption and Gastrointestinal immaturity comparing ELGN-2112 with Placebo (2 arms). Primary endpoint: Safety of ELGN-2112 compared with placebo. Started Jan 2023; status: active.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorptionGastrointestinal immaturity
Beyond the preview
Go deeper on 2022-004195-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004195-42.